TABRECTA GAINS FULL FDA APPROVAL FOR NON-SMALL CELL LUNG CANCER
The U.S. Food and Drug Administration (FDA) has approved the drug capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have a genetic mutation that results in the loss of exon 14 of the MET (mesenchymal-epithelial transition gene) gene. The approval was based on a trial of 160 patients with […]
TABRECTA GAINS FULL FDA APPROVAL FOR NON-SMALL CELL LUNG CANCER Read More »
